The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)
Time frame: Baseline through Week 20
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Superiority Analysis)
Time frame: Baseline through Week 20
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 20
Pharmacokinetics (PK): Average Concentration of LY3938577
Time frame: Baseline through Week 20
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tucson Clinical Research Institute
Tucson, Arizona, United States
RECRUITINGEncompass Clinical Research
Spring Valley, California, United States
RECRUITINGUniversity Clinical Investigators, Inc.
Tustin, California, United States
RECRUITINGTampa Bay Medical Research
Clearwater, Florida, United States
RECRUITINGEncore Medical Research
Hollywood, Florida, United States
RECRUITINGClinical Research of Central Florida
Lakeland, Florida, United States
RECRUITINGEncore Medical Research - Weston
Weston, Florida, United States
RECRUITINGIowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
RECRUITINGWashington University School of Medicine
St Louis, Missouri, United States
RECRUITINGAccellacare - Wilmington
Wilmington, North Carolina, United States
RECRUITING...and 16 more locations